The purpose of this call for proposals is to support clinical research activities that are part of a large-scale clinical trial with the potential to achieve rapid advances in the clinical development of new or improved medical interventions (drugs, vaccines, microbicides) or diagnostics, including multiplex diagnostic platforms, for poverty-related infectious diseases. These projects focus on phase III/IV study(ies) or advanced field testing (in the case of diagnostics). The proposed EDCTP2-funded study(ies) are conducted in sub-Saharan Africa but may form part of a larger trial that is conducted globally.
MTBVACN3
MTBVAC in Newborns: Randomised, double-blind controlled phase 3 trial to evaluate the efficacy, safety and immunogenicity of MTBVAC administered in healthy HIV-unexposed uninfected and HIV-exposed uninfected newborns in tuberculosis-endemic regions of sub-Saharan Africa
Biofabri S.L., Pontevedra, Spain, with partners from Madagascar, the Netherlands, Senegal, South Africa, Spain Project coordinator: Ms Ingrid Murillo Starting date: 01 January 2021 Duration: 60 months EDCTP grant amount: EUR 19,368,568 Grant agreement: RIA2019S-2652
We use cookies on our website to enhance your browsing experience, analyze site traffic, and personalize content. By clicking "Accept All," you consent to the use of all cookies. However, you may visit "Cookie Settings" to provide controlled consent.